Author

N. J. Dyson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:DNA methylation· 1

Frequent Co-Authors

M. S. Lawrence· 2 shared M. Stanzione· 2 shared A. Abbasi· 1 shared A. F. Farago· 1 shared A. Langenbucher· 1 shared A. N. Hata· 1 shared A. Riley· 1 shared A. T. Shaw· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

M. S. Lawrence

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Acquired Cross-resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC paralogs

S. Pal Choudhuri, L. Girard, J. Y. S. Lim, J. F. Wise, B. Freitas, D. Yang, E. Wong, S. Hamilton, V. Chien, S. Phat, C. Gilbreath, J. Zhong, D. T. Myers, C. L. Christensen, M. Stanzione, , B. J. Drapkin

This paper identifies extrachromosomal DNA amplification of MYC paralogs as a recurrent driver of acquired cross-resistance in small cell lung cancer using patient-derived xenograft models.

bioRxiv · Jun 23, 2023 · PreprintCancer Biology

APOBEC3A drives acquired resistance to targeted therapies in non-small cell lung cancer

H. Isozaki, A. Abbasi, N. Nikpour, A. Langenbucher, W. Su, M. Stanzione, H. Frisco-Cabanos, F. M. Siddiqui, N. Phan, P. Jalili, S. Oh, D. Timonina, S. Bilton, M. Gomez-Caraballo, H. L. Archibald, , A. N. Hata

This study shows that APOBEC3A mutagenesis driven by targeted therapies promotes drug resistance in non-small cell lung cancer.

bioRxiv · Jan 20, 2021Cancer Biology